B52, Hemo, I have felt the same way, becoming frustrated with the pace of a product that has such potential. Lately, I've also been thinking that we could be held back because of supply limitations. If we are currently manufacturing the filters at close to maximum capacity, how are we supposed to be able to supply expanding markets and additional therapies? We are kind of between a rock and a hard place, needing more capacity, but also needing the market to justify the expense. A good problem to have, but we must meet the demand when called upon. Our patients can not wait because the filter is on back order. I would like to have Dr. Chan address this problem. What is the value of Cytosorbents now at or near maximum capacity?
News 
Market Data 
Discover 
